Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - IOVANCE BIOTHERAPEUTICS, INC. | v439230_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 9, 2016
LION BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)
| NEVADA | ||
| (State of Incorporation) |
| 001-36860 | 75-3254381 | |||
| (Commission File Number) | (I.R.S. Employer Identification No.) |
| 112 W. 34th Street, 17th floor, New York, New York | 10120 | |||
| (Address of Principal Executive Offices) | (Zip Code) |
| 212-946-4856 | ||
| (Registrant’s Telephone Number, Including Area Code) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
ITEM 2.02. Results of Operations and Financial Condition.
On May 9, 2016, Lion Biotechnologies, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2016. A copy of that press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are included with this report:
| 99.1 | Press Release of Lion Biotechnologies, Inc., dated May 9, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: May 9, 2016 |
LION BIOTECHNOLOGIES, INC.
By: /s/ Molly Henderson
|